Acute Hepatic Porphyria (AHP)

American Association for the Study of Liver Diseases (AASLD) 2025

Congress Details

7-11 November 2025 | USA

Washington, D.C.

The materials in this section are intended for UK healthcare professionals and include scientific and educational congress content related to givosiran▼. The information contained in these presentations and posters was accurate at the time of presentation. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].

Congress Materials

Presentation Type

Presentation

Location

Washington, D.C.

Title

Clinical outcomes and hemin use of patients with acute hepatic porphyria in the phase 3 ENVISION study who were not attack-free after 6 months of givosiran treatment

Access Prescribing Information

Presentation Type

Poster

Location

Washington, D.C.

Title

Clinical outcomes and hemin use of patients with acute hepatic porphyria in the phase 3 ENVISION study who were not attack-free after 6 months of givosiran treatment

Access Prescribing Information

Presentation Type

Poster

Location

Washington, D.C.

Title

Dimension analysis of the ENVISION study EQ-5D data to assess the relationship between annualised attack rate and chronic symptoms in patients with acute hepatic porphyria